# Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety

> **NCT06816667** · PHASE1,PHASE2 · COMPLETED · sponsor: **Biomind Labs Inc.** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** BMND08
- **PROCEDURE:** Brain electrical activity monitor
- **DIAGNOSTIC_TEST:** Pharmacokinetic Study of Sublingually Administered Psychoactive Substance
- **DIAGNOSTIC_TEST:** Biochemical determinations
- **DIAGNOSTIC_TEST:** Acute Subjective Ratings of Psychedelic Effects
- **DIAGNOSTIC_TEST:** vital signs
- **DIAGNOSTIC_TEST:** Cognitive Assessments
- **DIAGNOSTIC_TEST:** Psychiatric Assessments

## Key facts

- **NCT ID:** NCT06816667
- **Lead sponsor:** Biomind Labs Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-21
- **Primary completion:** 2025-02-14
- **Final completion:** 2025-03-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06816667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06816667, "Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06816667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*